NPS Pharmaceuticals Inc (NPSP)

45.97
0.01 0.02
Prev Close 45.96
Open 45.96
Day Low/High 45.95 / 45.99
52 Wk Low/High 22.11 / 46.01
Volume 9.49M
Avg Volume 4.75M
Exchange
Shares Outstanding 108.58M
Market Cap 4.99B
EPS -0.08
Div & Yield N.A. (N.A)

Latest News

Cramer: Hold Your Fire

There isn't a lot of good news around.

Fibocall: NPS Pharmaceuticals

Fibocall: NPS Pharmaceuticals

 A new spike came on Wednesday, triggering an alert.

Putting Cash to Work

Putting Cash to Work

Some widely held stocks have dropped 10% in the past 24 hours. Portfolio Manager David Peltier discussed what he's buying.

Biotech's Next Big Thing: Earnings

Biotech's Next Big Thing: Earnings

It's time to review the mid-cap biotech stocks reporting second quarter results next week, says Adam Feuerstein, Sr. Columnist at TheStreet.

NPS Going Strong With Gattex

NPS Going Strong With Gattex

Sales of short bowel syndrome drug Gattex have been strong despite worries over price, says Francois Nader CEO of NPS Pharmaceuticals.

Mad Money Uncovered: Orphan Drug Stocks

Mad Money Uncovered: Orphan Drug Stocks

Jim Cramer discusses NPS Pharma and its orphan drug franchise with Nicole Urken, Mad Money Research Director.

Tuesday Trend Continues: Morning Movers

Tuesday Trend Continues: Morning Movers

U.S. stocks continue to trade higher on Tuesdays in 2013, as investors shift their focus away from Cyprus. Portfolio Manager David Peltier highlights early trading action.

The Next Big Thing in Biotech: FDA Decisions

The Next Big Thing in Biotech: FDA Decisions

Senior columnist Adam Feuerstein says three big FDA drug approval decisions are the next big things to watch in biotech.

Stocks Under $5: Blossoming Biotech Play

Stocks Under $5: Blossoming Biotech Play

Portfolio manager David Peltier discusses how to play one the most volatile low-dollar stocks of 2012.

Stocks Under $5: Live Twitter Chat

Stocks Under $5: Live Twitter Chat

Join Portfolio Mgr. David Peltier @davidspeltier on Twitter Thursday at 4:30 pm ET, for his #SU10chat

Stocks Under $10: Blossoming Biotech Play

Stocks Under $10: Blossoming Biotech Play

Portfolio manager David Peltier discusses a hot biotech stock with a promising clinical pipeline.

NPS Pharma CEO: Market Recognizing Pipeline Potential

NPS Pharma CEO: Market Recognizing Pipeline Potential

Francois Nader, CEO of NPS Pharmaceuticals, says the market is realizing the potential of its Gattex and Natpara drugs.